CSMYF Income Statement - Cosmos Pharmaceutical Corp - Alpha Spread

Watchlist Manager

Watchlist

Price: 48.271 USD -21.37% Market Closed

Market Cap: $3.9B

Metric	FY2017 May 2017	FY2018 May 2018	FY2019 May 2019	FY2020 May 2020	FY2021 May 2021	FY2022 May 2022	FY2023 May 2023	FY2024 May 2024	FY2025 May 2025	FY2026 May 2026
Revenue	502.7B	558B	611.1B	684.4B	726.4B	755.4B	827.7B	965B	1T	1.1T
Cost of Revenue	(402.7B)	(447.7B)	(489.4B)	(549.4B)	(581.3B)	(604B)	(659B)	(776.7B)	(798.1B)	(869.9B)
Gross Profit	100B	110.3B	121.8B	135B	145.1B	151.4B	168.7B	188.3B	213.3B	229.7B
Operating Expenses	(77.8B)	(87.6B)	(97B)	(105.9B)	(112B)	(121.7B)	(138.6B)	(156.8B)	(172.9B)	(187.3B)
Selling, General & Administrative	(68.1B)	(76.7B)	(85.1B)	(93.3B)	(99.2B)	(107.8B)	(122.8B)	(138.5B)	(152.4B)	(164.7B)
Depreciation & Amortization	(9.7B)	(10.9B)	(12B)	(12.5B)	(12.8B)	(13.9B)	(15.8B)	(18.3B)	(20.4B)	(22.6B)
Other Operating Expenses	(1m)	(1m)	(1m)	—	—	(1m)	(1m)	(1m)	—	—
Operating Income	22.2B	22.7B	24.8B	29.1B	33.1B	29.8B	30.1B	31.5B	40.4B	42.4B
Net Interest Income (Expense)	(13m)	(10m)	(5m)	(4m)	(3m)	0	(4m)	(55m)	(206m)	(507m)
Interest Expense	98m	88m	77m	69m	60m	52m	51m	99m	254m	581m
Non-Recurring Items	1.1B	(87m)	(154m)	(1.2B)	(1.4B)	(78m)	(313m)	(655m)	(788m)	(396m)
Gain/Loss on Disposition of Assets	—	—	—	—	4.2B	265m	—	75m	—	—
Total Other Income	2.4B	2.5B	2.5B	2.5B	2.7B	3.1B	3B	2.9B	3B	2.8B
Pre-Tax Income	25.7B	25.2B	27.1B	30.4B	38.6B	33B	32.8B	33.7B	42.4B	44.2B
Tax Provision	(7.5B)	(7.5B)	(8B)	(9B)	(11.4B)	(9.9B)	(9B)	(9.3B)	(11.4B)	(12.2B)
Income from Continuing Operations	18.2B	17.6B	19.2B	21.4B	27.2B	23.2B	23.8B	24.5B	31B	32B
Net Income	18.2B	17.6B	19.2B	21.4B	27.2B	23.2B	23.8B	24.5B	31B	32B
EPS (Diluted)	459.98	445.29	484.48	541.30	685.77	292.37	300.48	308.61	390.85	404.33

Continue CSMYF Research

Relative Valuation

Wall St Estimates

Financial Statements